Immatics presents clinical activity of Ima402 and Ima203CD8 in advanced solid tumors
IMTX•Immatics presented clinical activity from two oral presentations at the 2026 ESMO Annual Meeting. Ima203CD8 showed a 55% CORR and 8.4-month median DOR in gynecologic cancers; Ima402 achieved a 32% CORR, 12.5-month median DOR and 91% 1-year OS rate in advanced melanoma patients with high PRAME expression.
1. Clinical results presented
Immatics said Ima203CD8 showed a 55% CORR and 8.4-month median DOR in gynecologic cancers. Ima402 demonstrated anti-tumor activity and a favorable safety profile across multiple indications, with a 32% CORR, 12.5-month median DOR and 91% 1-year OS rate among advanced melanoma patients with high PRAME expression.
